NewAmsterdam Pharma (NAMS) Insider Trading & Ownership $22.41 -0.15 (-0.66%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$22.42 +0.02 (+0.07%) As of 03/27/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NewAmsterdam Pharma (NASDAQ:NAMS) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage19.50%Number OfInsiders Buying(Last 12 Months)3Amount OfInsider Buying(Last 12 Months)$187,817.90Number OfInsiders Selling(Last 12 Months)2Amount OfInsider Selling(Last 12 Months)$15.20 M Get NAMS Insider Trade Alerts Want to know when executives and insiders are buying or selling NewAmsterdam Pharma stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address NAMS Insider Buying and Selling by Quarter Remove Ads NewAmsterdam Pharma Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails3/4/2025James N TopperDirectorBuy4,005$21.02$84,185.10 3/4/2025Louise Frederika KooijCAOSell150,000$20.37$3,055,500.00 12/30/2024Nap B.V. ForgrowthMajor ShareholderSell29,846$25.54$762,266.84 12/26/2024Nap B.V. ForgrowthMajor ShareholderSell33,438$26.01$869,722.38 12/23/2024Nap B.V. ForgrowthMajor ShareholderSell25,132$25.49$640,614.68 12/20/2024Nap B.V. ForgrowthMajor ShareholderSell49,772$25.60$1,274,163.20 12/18/2024Nap B.V. ForgrowthMajor ShareholderSell100,728$26.10$2,629,000.80 12/12/2024Nap B.V. ForgrowthMajor ShareholderSell166,011$25.39$4,215,019.29 11/18/2024Nap B.V. ForgrowthMajor ShareholderSell33,273$25.08$834,486.84 11/15/2024Nap B.V. ForgrowthMajor ShareholderSell8,530$25.02$213,420.60 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 10/1/2024Louise Frederika KooijCAOSell45,000$15.72$707,400.00 9/26/2024Juliette Berangere AudetInsiderBuy1,104$15.70$17,332.80 6/20/2024Michael H DavidsonCEOBuy5,000$17.26$86,300.00 (Data available from 1/1/2013 forward) NAMS Insider Trading Activity - Frequently Asked Questions Who is on NewAmsterdam Pharma's Insider Roster? The list of insiders at NewAmsterdam Pharma includes James N Topper, Johannes Jacob Piete Kastelein, Juliette Berangere Audet, Louis G Lange, Louise Frederika Kooij, Michael H Davidson, and Nap B.V. Forgrowth. Learn more on insiders at NAMS. What percentage of NewAmsterdam Pharma stock is owned by insiders? 19.50% of NewAmsterdam Pharma stock is owned by insiders. Learn more on NAMS's insider holdings. Which NewAmsterdam Pharma insiders have been buying company stock? The following insiders have purchased NAMS shares in the last 24 months: James N Topper ($265,408.60), Juliette Berangere Audet ($17,332.80), Louis G Lange ($95,000.00), and Michael H Davidson ($86,300.00). How much insider buying is happening at NewAmsterdam Pharma? Insiders have purchased a total of 23,538 NAMS shares in the last 24 months for a total of $464,041.40 bought. Which NewAmsterdam Pharma insiders have been selling company stock? The following insiders have sold NAMS shares in the last 24 months: Johannes Jacob Piete Kastelein ($4,095,234.00), Louise Frederika Kooij ($3,762,900.00), and Nap B.V. Forgrowth ($11,438,694.63). How much insider selling is happening at NewAmsterdam Pharma? Insiders have sold a total of 832,206 NewAmsterdam Pharma shares in the last 24 months for a total of $19,296,828.63 sold. NewAmsterdam Pharma Key ExecutivesDr. Michael Harvey Davidson FACC (Age 68)Facp., M.D., CEO, President, Executive Board Member & Director Compensation: $885.6kDr. Johannes Jacob Pieter Kastelein FESC (Age 70)M.D., Ph.D., Founder, Chief Scientific Officer, Member of Executive Board & Director Compensation: $677.76kMr. Mayur Amrat Somaiya (Age 50)Chief Financial Officer Compensation: $402.3kMs. Juliette Audet M.B.A. (Age 37)M.Sc., Chief Business Officer Compensation: $45.62kMr. Douglas F. Kling (Age 51)Chief Operating Officer Ms. Louise Kooij (Age 48)Chief Accounting Officer Mr. Matthew PhilippeExecutive VP &Head of Investor RelationsMr. Jim JacobsonChief Legal Officer & SecretaryMr. Bob RamboExecutive Vice President of MarketingDr. Marc Ditmarsch M.D. (Age 57)Chief Development Officer More Insider Trading Tools from MarketBeat Related Companies PCVX Insider Transactions ROIV Insider Transactions SRPT Insider Transactions RVMD Insider Transactions LNTH Insider Transactions TGTX Insider Transactions BBIO Insider Transactions AXSM Insider Transactions BPMC Insider Transactions KRYS Insider Transactions Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles NVIDIA Insiders Sell: This Is What It Means for the Market Top 3 Insider Stock Buys in March—Are They Still Good in April?Grocery Outlet Insider and Institutional Buyers Signal BottomSentinelOne Insider Selling? Why Investors Should Stay Bullish 3 Companies Buying Back Stock—Why It Matters This page (NASDAQ:NAMS) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersA $6.9 Trillion Cash Tsunami Is Coming – Move Your Money NOWExpert: "Prepare For the Mother of All Melt-Ups" In the wake of Wall Street volatility, stock-picking legen...Stansberry Research | SponsoredElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredAI Boom Takes a Shocking Turn…A potentially historic moment for retirement Let's make the most of this market together. Crypto 101 Media | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NewAmsterdam Pharma Please log in to your account or sign up in order to add this asset to your watchlist. Share NewAmsterdam Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NAMS Stock Free NAMS Stock Alerts